Celecoxib

Evidence Level: L5

Predicted Indications: 7

Celecoxib

Pharmacist Assessment Report

Celecoxib: COX-2 inhibitor (NSAID) → acromesomelic dysplasia, Hunter-Thompson type

One-Sentence Summary

Celecoxib is a selective COX-2 inhibitor, a type of nonsteroidal anti-inflammatory drug (NSAID), marketed in Australia as an oral capsule. The TxGNN model predicts it may be relevant to acromesomelic dysplasia, Hunter-Thompson type, but no clinical trials and no publications currently support this prediction. The prediction is model-based only (evidence level L5).

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score	0.9988
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Celecoxib is known as a selective COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain.

Acromesomelic dysplasia, Hunter-Thompson type, is a rare skeletal dysplasia linked to a defect in the CDMP1/GDF5 gene, which is involved in skeletal development. A connection between COX-2/prostaglandin signalling and skeletal development is conceivable, but it is speculative and unsupported by any study in the compiled data. The high TxGNN score reflects a model-based prediction only, not a demonstrated mechanistic rationale. Because the underlying problem is a genetic developmental defect, an anti-inflammatory drug is not expected to correct it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 8439E	Celebrex	Capsule 100 mg	Not recorded in the local data

The compiled data list one valid single-ingredient licence and no cancelled licences.

Cytotoxicity

Celecoxib is not an antineoplastic drug, so this section does not apply.

Safety Considerations

Label-based warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Drug interactions (100 interactions were identified in the data compiled for this report; the list below is a sample):

Major: eliglustat
Moderate: hydrocortisone, metformin, several sulfonylureas (acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide), nateglinide, exenatide, balsalazide, mesalazine, olsalazine, cimetidine, levofloxacin, metronidazole, kanamycin, naltrexone, fenfluramine, dexfenfluramine

Conditions of concern in the compiled data (not from label text) include hypertension, kidney disease, liver disease, congestive heart failure, peptic ulcer disease, asthma, stroke and cerebrovascular disorders, myocardial infarction and other cardiovascular disease, anaemia, and substance abuse/dependence. These should be checked against the PI.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a high TxGNN score (0.9988), with no clinical trials, no publications and no supported mechanistic link for this rare skeletal dysplasia. Evidence level is L5.

To proceed, the following is needed:

Mechanistic evidence linking COX-2/prostaglandin pathways to GDF5/CDMP1-related skeletal development
Preclinical studies in relevant disease models
Detailed mechanism of action data for celecoxib
Review of the TGA-approved PI for warnings and contraindications
Risk-benefit assessment for a rare paediatric-onset skeletal condition, given the cardiovascular, gastrointestinal and renal risks of long-term NSAID use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.